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Abstract 
Background: Recent genome-wide association studies have identified genetic loci that jointly make a 
considerable contribution to risk of developing Alzheimer’s disease (AD). Because neuropathological 
features of AD can be present several decades before disease onset, we investigated whether effects 
of polygenic risk are detectable by neuroimaging in young adults. We hypothesised that higher 
polygenic risk scores (PRS) for AD would be associated with reduced volume of the hippocampus, 
and other limbic and paralimbic areas. We further hypothesised that AD PRS would affect the 
microstructure of fibre tracts connecting the hippocampus with other brain areas.  
Methods: We analysed the association between AD PRS and brain imaging parameters using T1-
weighted structural (n=272) and diffusion-weighted scans (n=197). 
Results: We found a significant association between AD PRS and left hippocampal volume, with 
higher risk associated with lower left hippocampal volume (p=0.001). This effect remained when the 
APOE gene was excluded (p=0.031), suggesting that the relationship between hippocampal volume 
and AD is the result of multiple genetic factors, not exclusively variability in the APOE gene.  The 
diffusion tensor imaging analysis revealed that fractional anisotropy of the right cingulum was 
inversely correlated with AD PRS (p=0.009). We thus show that polygenic effects of AD risk variants 
on brain structure can already be detected in young adults. 
Conclusions: This finding paves the way for further investigation of the effects of AD risk variants 
and may become useful for efforts to combine genotypic and phenotypic data for risk prediction and 
to enrich future prevention trials of AD.  
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1. Introduction 
Alzheimer’s disease (AD) is the most common neurodegenerative disease, affecting about 5%-7% of 
the population over 60 years of age (1).  Although a small proportion of cases, often with a younger 
onset, are caused by autosomal dominant mutations, the vast majority of cases do not follow 
Mendelian heritability. Such “sporadic” AD is mediated by both environmental and genetic factors, 
with many genes contributing different degrees of risk (2). The most highly penetrant common 
genetic risk factor for AD is the apolipoprotein (APOE) ε4 allele, each copy of which increases AD risk 
by a factor of about 3 (3). However, recent genome-wide association studies (GWAS) have identified 
a further 19 genome-wide significant loci for AD (4-6), which provide new insights into possible 
biological mechanisms underlying the neurodegenerative process (7). Individually the most powerful 
of these variants only marginally increase an individual’s risk for developing AD (~1-8%) (4). 
Polygenic risk scores (PRS), which are based on the additive effect of multiple loci across the 
genome, may be better suited to capture the variance explained by common alleles (8). PRS based 
on the most recent GWAS have considerable predictive utility for AD risk (9) .  
Structural brain imaging has consistently revealed both global and local atrophic changes in patients 
with AD (10), and is a useful biomarker for preclinical disease (11) . Local atrophy in medial temporal 
areas including the hippocampus, is observed early in the course of the disorder (12, 13) and in 
patients with Mild Cognitive Impairment (MCI) (14), a clinical state which may be a precursor to AD 
(15). Hippocampal atrophy predicts conversion from MCI to AD (16), and has also been reported in 
carriers of rare dominant AD risk variants in the genes coding for amyloid precursor protein and 
presenilin 1 (17) as well as carriers of highly penetrant common variants such as APOE ε4 (18). 
Indeed hippocampal volume is already a key imaging phenotype to identify preclinical stages of AD 
(19). Other brain structures showing significant atrophy early in disease progression include other 
medial temporal lobe (MTL) regions including the entorhinal cortex (ERC) (20, 21), parahippocampal 
gyrus (PHG) (22) and posterior cingulate gyrus (PCG) (23). We therefore focused on early changes in 
these structures. 
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The combination of PRS and neuroimaging data is likely to be particularly informative in identifying 
markers of early risk for AD (24, 25), even before the putative onset of amyloid accumulation. In the 
current study, we sought to investigate the correlation between polygenic risk for AD, based on the 
largest genetic training dataset available (4), and grey and white matter structural differences in a 
healthy young population without any signs of cognitive impairment. So far the only studies 
conducted with AD PRS have used 24 risk loci (26) or PRS derived from a smaller AD GWAS (23, 27), 
making ours the genetically most powerful study conducted on this topic to date. 
We predicted that the PRS for AD would be negatively correlated with hippocampal volume. We 
were also interested in exploring the association of cortical thickness of ERC, PHG and PCG, due to 
the involvement of these areas in early AD (28-30), where we would expect to see a decrease in 
thickness. In addition to grey matter parameters, we also investigated the microstructure of the 
main white matter pathways connecting our candidate areas, in order to ascertain whether any grey 
matter loss would already have impacted on the fibre tracts by way of anterograde or retrograde 
degeneration. We measured fractional anisotropy (FA), a measure of white matter microstructure 
derived from diffusion tensor imaging (DTI) (31) in the main connecting tracts of the hippocampus; 
the cingulum and the fornix. We expected FA to be lower in participants with higher AD PRS. 
 
2. Methods and Materials 
2.1 Participants  
Brain scans used in this study were obtained from a repository of neuroimaging and genetic data 
obtained between 2009 and 2014 from healthy subjects recruited through a range of research 
projects at Cardiff University Brain Research Imaging Centre (CUBRIC), which has received ethical 
approval from the Cardiff University School of Psychology. All subjects were screened for the 
exclusion of any neuropsychiatric disorders either by interview or questionnaires. Participants 
provided informed consent for genotyping and use of their imaging data for genetic imaging 
analysis. After genotyping and data quality control standards, 272 individuals with structural T1 data 
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remained (195 female, 77 male) with an average age at time of inclusion of 24.8 (SD 6.9). 
Tractography data was available for a subset of 197 participants (138 female, 59 male) with an 
average age at time of inclusion of 23.9 (SD 5.1). For a subgroup of 87 participants (53 female, 34 
male, mean age 23.9 (SD 4.4)) data on the Hopkins Verbal Learning Task were available. This task 
measures declarative verbal learning capacity (32) and forms part of the MATRICS Consensus 
Cognitive Battery.  
2.2 Genotyping  
Genomic DNA was obtained from saliva using Oragene OG-500 saliva kits (DNA Genotek, Inc., 
Ontario, Canada). Genotyping was performed using custom Illumina HumanCoreExome-24 BeadChip 
genotyping arrays, which contain 570,038 genetic variants (Illumina, Inc., San Diego, CA). Quality 
control was implemented in PLINK (33). Individuals were excluded for any of the following reasons: 
(1) ambiguous sex (genotypic sex and phenotypic sex not aligning); (2) cryptic relatedness up to third 
degree relatives as ascertained using identity by descent; (3) genotyping completeness less than 
97%; and (4) non-European ethnicity admixture. The latter was detected as outliers in an iterative 
EIGENSTRAT analysis of a LD-pruned dataset (34). SNPs were excluded where the minor allele 
frequency was less than 1%, if the call rate was less than 98% or if the χ2-test for Hardy-Weinberg 
Equilibrium had a p-value less than 1x10-4. Individuals’ genotypes were imputed using the pre-
phasing/imputation stepwise approach implemented in IMPUTE2/SHAPEIT (35, 36) and 
1000Genomes (December 2013, release 1000 Genomes haplotypes Phase I integrated variant set) as 
the reference dataset. This resulted in a dataset of 274 individuals with information for 7,413,342 
SNPs. 
2.3 Polygenic scoring method  
Polygenic score calculations were performed according to the procedure described by the 
International Schizophrenia Consortium (37). Training data was from the IGAP consortium that 
comprises 17,008 AD cases and 37,154 controls. (4). This data is publicly available from 
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http://www.pasteur-lille.fr/en/recherche/u744/igap/igap_download.php. SNPs were removed from 
all analyses if they had a low minor allele frequency (MAF<0.01). Subsequently the data was pruned 
for linkage disequilibrium using the clumping function (--clump) in PLINK (Purcell, Neale et al. 2007) 
removing SNPs within 500kb (--clump-kb) and r2>0.25 (--clump-r2) with a more significantly 
associated SNP.  We used the --score command in PLINK to calculate polygenic scores (33). Nine 
different progressive training p-value thresholds (38) were investigated (PT< 1x10
-8, 1x10-7,1x10-6, 
1x10-5, 1x10-4, 0.01, 0.1, 0.3, and 0.5). Lower PT indicate SNPs are more significantly associated with 
AD case status in the training dataset (AD case control study (4)).    
These polygenic risk scores include the APOE loci on chromosome 19, the greatest common genetic 
risk factor for AD. If a significant association was observed between AD PRS and brain imaging 
phenotypes, the data was reanalysed with polygenic scores excluding any SNPs within the APOE 
locus (chr19: 45.053-45.73 Mb), to assess if the association was purely due to variance in APOE.  
 
2.4 MR Imaging data  
2.4.1 Data acquisition 
MRI imaging was carried out in CUBRIC on a GE Signa HDx 3T scanner (GE Healthcare, Milwaukee 
WI). T1-weighted structural data were acquired using an axial 3D fast, spoiled gradient recalled 
(FSPGR) sequence with the following parameters; TR/TE/TI = 8 / 3 / 450 ms; flip angle = 20deg; 1mm  
resolution; field of view ranging from 256x192x160 mm^3 to 256x256x256 mm^3 (AP-LR-SI), with 
acquisition time ranging from approx. 6 minutes to 10 minutes. 
 DTI data were acquired using a cardiac-gated sequence with the following parameters; b-values 0 
and 1200, TR~20s (dependent on heart rate); TE=90ms; 60 2.4mm slices aligned with the AC-PC, zero 
slice gap; acquisition matrix 96x96; field of view = 230 mm; 2.4mm isotropic resolution.  Data were 
either acquired from 30 unique diffusion directions plus 3 b0 images, or from a sub-sample of 30 
optimal directions from an acquired set of 60 directions, with the first 3 b0 images. 
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2.4.2 Data processing  
Hippocampal volume, ERC, PHG, PCG thickness and intracranial volume (ICV) were determined 
through analysis with FreeSurfer (surfer.nmr.mgh.harvard.edu) which has been validated as a 
suitable method for hippocampal segmentation in large samples (39). The resulting output was 
quality controlled following a publically available protocol from ENIGMA (http://enigma.ini.usc.edu/) 
(40). Whenever a region of interest (ROI) was detected as inadequately segmented by XC or SF, its 
metric was declared missing and excluded from analysis. The numbers of brain regions included in 
the final analysis were: Hippocampus right and left n=270, entorhinal cortex left n=257 and right 
n=268, posterior cingulate gyrus left n=272 and right n=271, parahippocampal gyrus left n=259 and 
right n=271. 
DTI data were analysed using ExploreDTI (41) version 4.8.3 and were corrected for eddy current 
distortions and subject motion using an affine registration to the non-diffusion-weighted images, 
with appropriate re-orienting of the encoding vectors (42). An echo planar imaging (4) correction 
was applied, warping the DTI data to the FSPGR images resulting in a 1x1x1 mm³ resolution in the 
resulting output. A single diffusion tensor model was fitted to the DTI data (43) in order to compute 
quantitative parameters such as FA. 
Subsequently the damped Richardson Lucy (dRL) pipeline (44) was used to perform whole brain 
tractography. Termination criteria were an angle threshold greater than 45°, streamlines were 
terminated when the magnitude of the minimally subtending fibre orientation density function 
(fODF) peak falls below 0.05. Tracts were obtained using in-house automated tractography software 
(45).  The automated tractography models for the fornix, cingulum and PHC were based on manual 
tractography performed by SF. Each automated tract underwent quality control through visual 
inspection, and was brought to manual tractography standards by post-hoc removal of any fibre 
bundles considered spurious, where necessary. Final numbers of tracts included were fornix n=157, 
cingulum and PHC right and left n=197. The fornix was defined according to Jones et al. (46) the high 
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levels of drop out are most probably due to the high curvature of the tract and proximity to the 
ventricles. To segment the PHC the restricted method was used, which incorporates a ‘NOT’ gate 
blocking inclusion of all tracts projecting towards the frontal cortex (47). For an example of the tracts 
see Figure 2. Free water correction was applied (48, 49) before extracting FA values for further 
analysis. FA values were extracted using customised MATLAB scripts (The MathWorks, Natick, MA, 
USA). 
 
2.5 Analysis 
Regional thickness data determined from T1 scans, were analysed using hierarchical linear multiple 
regression in IBM SPSS statistics 20 (IBM Corp, Armonk, NY, USA), co-varying for age, gender and ICV. 
The hippocampal volumes were adjusted for ICV of each participant with the formula: Hippocampal 
volume corrected = Hippocampal volume -(beta*(ICV-mean ICV across the group studied))(50). 
Subsequently they were analysed using hierarchical linear multiple regression co-varying for age and 
gender. 
 The DTI data were also analysed using hierarchical linear multiple regression, including FA as the 
dependent variable and controlling for independent variables age, gender and scan type (30 or 
downsampled 60 directions). 
The p-values were then corrected for multiple comparisons using False Discovery Rate (FDR), in 
statistics package R (51), resulting in q-values. FDR was applied over the ROIs studied. Where 
significant results remained after FDR correction, further analysis was performed using the PRS 
without APOE SNPs.  
 It is standard practise to compare PRS scores over multiple thresholds (37) and it is difficult to 
correct for multiple comparisons due to the highly correlated nature of the thresholds. Permutation 
testing is a robust way to correct for multiple comparisons in a dependent sample (52). The 
supplement contains an outline of permutation tests performed on all the nominally significant 
results.  
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3. Results 
3.1 Hippocampal volume 
PRS scores correlated negatively with left hippocampal volume corrected for intracranial volume 
(R2=0.039; p=0.001; q=0.008; PT<1x10
-4), as demonstrated in Table 1. PRS calculated at all PTs were 
nominally associated with decreased left hippocampal volume, and 4 of these survived correction for 
multiple testing (Table 1).  Analysis of the R² change showed that the PRS accounted for an 
additional 1.9 – 3.9% of the variance in left hippocampal volume over the 9 thresholds, after 
removing variance explained by age and gender, which accounted for 0.5%. No such effect was seen 
in the right hippocampus, where R² change ≤0.001 across the whole range of PRS thresholds. 
Subsequent analysis of hippocampal volume with the APOE locus removed from PRS, showed that 
the significant association between AD PRS and decreased left hippocampal volume persisted 
(R2=0.022; p=0.014; PT<0.01), particularly with the more inclusive PTs.  
3.2 Entorhinal cortex, posterior cingulate gyrus, and parahippocampal gyrus thickness  
No significant effects of AD PRS were seen on the volume of the ERC or PHG. A small increase in 
volume was seen in the left PCG, which was conserved at one threshold (R2=0.025; p=0.006; 
q=0.048; PT<0.1), after correction for multiple comparisons. This effect persisted after removal of the 
APOE locus from the PRS (Table 1). 
3.3 Tractography fornix, cingulum and PHC 
No effect was found of AD PRS on FA in the fornix or PHC (Table 2). However a significant effect was 
found of AD PRS on FA of the right cingulum (R2=0.032; p=0.009; q=0.045; PT<1x10
-4), with a negative 
association between PRS and FA at 5 thresholds. This effect was conserved for 1 of these thresholds 
(p≤0.05) when correcting for multiple comparisons over all 5 ROIs. Subsequent analysis of cingulum 
FA, excluding the APOE locus from the AD PRS, only showed a significant association at one 
threshold (R2=0.019; p=0.044; PT<1x10
-6
).  
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3.4 Cognitive effects  
We found no correlation between scores on the Hopkins Verbal Learning Task and polygenic risk for 
AD (see Supplemental Table S1). 
4. Discussion 
As predicted, PRS for AD was associated with lower hippocampal volume. While hippocampal 
volume reductions in patients are a robust finding in AD (10, 13) and MCI patients converting to AD 
undergo greater hippocampal atrophy (16), previous reports of hippocampal volume effects of 
genetic risk variants in healthy subjects have been varied. Some studies (53-55) found no effect of 
APOE risk alleles on hippocampal volume in young participants, while others found a significant 
difference between young ε4 and ε2 carriers (18). Previously right but not left hippocampal volume 
reductions were found in APOE ε4 risk allele carriers in comparison to ε3 carriers in a middle aged 
population (56), whereas we find effects in the left but not right hippocampus. However, most of the 
previous literature has reported a slight preponderance of left compared to right hippocampal 
changes, particularly in the preclinical and early stages of AD progression (57), which would be in line 
with our findings.  
We may see significant effects where others have obtained mixed results with single locus studies 
because of the benefits of using polygenic risk scores. Although the SNPs contributing to the PRS 
have much smaller individual effect sizes than the APOE locus, cumulatively they explain a large 
amount of variance (58).  
Although previous reports have implicated the ERC in AD pathology (20, 21), we do not see an effect 
of AD genetic risk on ERC thickness. This is consistent with previous studies (38), which failed to find 
an effect of APOE on ERC thickness in a healthy middle aged and older adult population. Conversely, 
the small increase in PCG thickness was unexpected because both manifest AD and genetic risk 
status have been associated with thinning of this area (59, 60). Replication of this finding in future 
studies would be needed before strong conclusions can be drawn.   
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It has been proposed that AD, like many other neuropsychiatric disorders, is a disconnection 
syndrome (61). Connectivity models of pathophysiology can be supported by the investigation of the 
microstructural properties of white matter. Changes in white matter parameters have indeed been 
observed in many DTI studies of AD, for example decreased FA in the right fornix (10) and the left 
PHC (62), superior longitudinal fasiculus, temporal lobe (63, 64) and cingulum (65). A significant 
decrease of FA  was also found in the PHC in MCI patients (66). Differences in FA relating to AD risk 
genes have previously been observed in healthy participants as well; APOE ϵ4 was linked to 
alterations in FA in the left MTL and in the corpus callosum in healthy individuals (67). One study 
found widespread FA decreases in a young healthy population (age 20-35) with APOE risk variants 
(68), while another found widespread decreases in FA, including in the fornix and cingulum, in young 
individuals carrying the clusterin risk allele (69). A population of preclinical subjects with an 
autosomal dominant AD variant  also had significantly lower FA in the columns of the fornix (70). 
Our finding of reduced FA in the right cingulum, which was not exclusively driven by the APOE locus, 
is in line with models that assume early white matter changes in the course of the development of 
AD pathology. The fact that this correlation between cingulum FA and AD PRS was not driven by the 
PHC, which connects the medial temporal lobe with areas in the parietal and occipital lobes such as 
the posterior cingulate cortex (47), was contrary to expectations. In our sample the white matter 
findings were not directly related to the grey matter structural differences, which occurred in the 
opposite hemisphere.  
We used the results from the largest AD GWAS undertaken to date, as our training data (4). 
Therefore, the estimates of SNP effects on AD risk utilized in this study are the best reported to date 
with better power than previous estimates, as it is known that polygenic risk score and R2 values are 
highly affected by the sample size of the training dataset (71). 
Hippocampal volume and cortical thickness are highly heritable which makes them appropriate 
parameters for genetic imaging analysis (72, 73). A limitation of our study is that, by the nature of 
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the polygenic analysis, which pools risk variants across the whole genome, no inferences can be 
made on the specific molecular mechanisms contributing to the structural brain differences. 
Although neurofibrillary tangles can be present in the hippocampus in young adults, the Braak 
staging model would suggest that entorhinal/ transentorhinal cortex is affected even earlier by this 
process (74, 75). Although amyloid pathology can be detected in young carriers of Mendelian 
variants affecting the amyloid pathway (76) it would be unlikely to be confined to the hippocampus 
(75), and our sample was probably too young to have a significant amyloid load (77). GWAS for AD 
have revealed novel pathways  associated with AD including in lipid metabolism, immune responses 
and endocytosis, while also finding no enrichment of genes associated with either tau or amyloid 
pathways, suggesting other factors may play a role in risk and development of AD (7). Furthermore, 
it is possible that the cumulative effect of common AD risk variants affects the development of the 
hippocampus in a similar way as they have been shown to affect cognition across the life course of 
an individual (78). Longitudinal studies of genetic imaging, involving even younger populations than 
that of the present study, and pathway-based analysis (79-81) will be needed to address the 
biological significance of our findings. However pathway-based analyses will likely require larger 
samples and new approaches to the multiple testing problem. 
In conclusion, AD polygenic risk was associated with smaller volume of the left hippocampus, 
increased volume of left PCG and lower FA in the right cingulum bundle in healthy young adults. 
Thus, AD genetic risk can be linked to structural differences in brain areas that have been implicated 
in the early stages of AD pathology many decades before potential illness onset. This effect was not 
driven exclusively by contributions from APOE as the associations persisted after removal of the 
APOE locus. Overall this work suggests that genetic risk for AD is mediated, in part, through brain 
morphological differences, mainly in the hippocampus, confirming hippocampal volume changes as 
an important early biomarker of risk for AD.  
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Table legends 
 
Table 1: The influence of polygenic AD risk scores on brain structure: R2 change and p-values for 
hippocampal volume left (L n=270) and right (R n=270), entorhinal cortex thickness (ERC L n=257; 
ERC R n=268), posterior cingulate gyrus thickness (PCG L n= 272; PCG R n=271) and parahippocampal 
gyrus thickness (PHGL n=259; PHG R n=271). The top axis shows the ROI while the vertical axis shows 
the polygenic threshold. * denotes q-FDR corrected <0.05. Bold and italicised results denote 
nominally significant associations (p-value<0.05.) 
Table 2: R squared change and p-values for the change in FA correlating with AD PGS for each 
threshold. Fornix (n=157), Cingulum left (n=197)and right (n=197) (with and without APOE SNPs), 
and Parahippocampal Cingulum left (n=197) and right (n=197) are shown here. Bold and italicised 
results denote nominally significant associations (p-value<0.05.). Associations that survive FDR 
correction are denoted by * asterisk. 
 
Figure legends 
 
Figure 1: Effects of polygenic risk scores on regions of interest before false discovery rate correction. 
Vertical axis denotes the R² change, with upwards indicating an increase and downwards indicating a 
decrease of volume or thickness of the region of interest.   
 
Figure 2: A: Coronal view of fornix fibres. B: Sagittal view of right cingulum fibres. C: Sagittal view of 
right PHC fibres. 
 
Table 1 
 
Training 
P-value 
Threshold 
Hippo-
campus 
L R2(p-
value) 
Hippo-
campus 
L No 
APOE 
R2 (p-
value) 
Hippo-
campus 
R R2 (p-
value) 
ERC L  
R2 (p-
value) 
ERC R  
R2 (p-
value) 
PCG L 
R2 (p-
value) 
PCG L 
No 
APOE 
R2 (p-
value) 
PCG R 
R2 (p-
value) 
PHG L 
R2 (p-
value) 
PHG R R2 
(p-
value) 
PT<1 x10-8 0.019 
(0.024) 
<0.001 
(0.966) 
<0.001 
(0.795) 
<0.001 
(0.742) 
0.009 
(0.118) 
0.005 
(0.224) 
0.003 
(0.391) 
0.002 
(0.500) 
0.003 
(0.386) 
0.003 
(0.393) 
PT<1x10-7 0.020 
(0.021) 
<0.001 
(0.991) 
0.001 
(0.683) 
<0.001 
(0.869) 
0.009 
(0.127) 
0.005 
(0.213) 
0.001 
(0.550) 
0.002 
(0.486) 
0.002 
(0.433) 
0.004 
(0.325) 
PT<1x10-6 0.023 
(0.012) 
0.003 
(0.409) 
<0.001 
(0.814) 
<0.001 
(0.833) 
0.006 
(0.215) 
0.005 
(0.215) 
<0.001 
(0.788) 
0.003 
(0.362) 
0.002 
(0.522) 
0.005 
(0.227) 
PT<1x10-5 0.034 
(0.002)* 
0.019 
(0.023) 
<0.001 
(0.958) 
<0.001 
(0.873) 
0.007 
(0.173) 
0.006 
(0.201) 
0.001 
(0.635) 
0.004 
(0.287) 
0.001 
(0.592) 
0.005 
(0.256) 
PT<1x10-4  0.039 
(0.001)* 
0.017 
(0.031) 
<0.001 
(0.932) 
0.001 
(0.620) 
0.009 
(0.128) 
0.011 
(0.073) 
0.009 
(0.112) 
0.007 
(0.156) 
0.002 
(0.481) 
0.006 
(0.212) 
PT<0.01 0.035 
(0.002)* 
0.022 
(0.014) 
<0.001 
(0.933) 
0.005 
(0.257) 
0.007 
(0.181) 
0.015 
(0.034) 
0.012 
(0.060) 
0.001 
(0.554) 
0.003 
(0.406) 
0.012 
(0.076) 
PT<0.1 0.023 
(0.012)* 
0.017 
(0.032) 
<0.001 
(0.863) 
0.004 
(0.289) 
0.005 
(0.253) 
0.025 
(0.006)* 
0.023 
(0.009) 
0.001 
(0.645) 
0.010 
(0.109) 
0.010 
(0.099) 
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PT<0.3 0.022 
(0.015) 
0.017 
(0.033) 
<0.001 
(0.850) 
0.002 
(0.512) 
0.006 
(0.206) 
0.019 
(0.019) 
0.017 
(0.025) 
0.002 
(0.488) 
0.009 
(0.123) 
0.010 
(0.094) 
PT<0.5 0.021 
(0.017) 
0.016 
(0.037)  
<0.001 
(0.748) 
0.002 
(0.530) 
0.009 
(0.123) 
0.021 
(0.014) 
0.019 
(0.019) 
0.002 
(0.483) 
0.012 
(0.082) 
0.009 
(0.128) 
 
Table 2 
 
Training 
P-value 
Threshold 
Fornix 
R2 (p-
value) 
Cingulum L 
R2 (p-value) 
Cingulum R 
R2 (p-value) 
 
Cingulum R 
No APOE 
R2 (p-value) 
PHC L  
R2 (p-value) 
PHC R  
R2 (p-
value) 
PT<1 x10-8 <0.001 
(0.791) 
0.009(0.164) 0.030(0.011) 0.006(0.254) 0.008(0.194) 0.002(0.534) 
PT<1x10-7 <0.001 
(0.813) 
0.009(0.162) 0.029(0.013) 0.006(0.268) 0.006(0.233) 0.002(0.515) 
PT<1x10-6 <0.001 
(0.813) 
0.005(0.270) 0.023(0.026) 0.019(0.044) 0.006 (0.255) 0.002(0.538) 
PT<1x10-5 <0.001 
(0.846) 
0.004(0.344) 0.025(0.020) 0.006(0.270) 0.005(0.292) 0.001(0.655) 
PT<1x10-4 <0.001 
(0.780) 
0.009(0.165) 0.032(0.009)* <0.001(0.885) 0.002(0.547) <0.001 
(0.949) 
PT<0.01 <0.001 
(0.952) 
0.001(0.610) 0.006(0.273) <0.001 
(0.858) 
0.003(0.432) 0.001(0.727) 
PT<0.1 <0.001 
(0.886) 
0.001(0.626) 0.005(0.305) 0.001 (0.588) 0.005(0.289) 0.006(0.268) 
PT<0.3 <0.001 
(0.840) 
0.003(0.440) 0.002(0.493) <0.001 
(0.777) 
0.003(0.388) 0.004(0.357) 
PT<0.5 <0.001 
(0.806) 
0.002(0.486) 0.002(0.471) 0.001 (0.731) 0.003(0.387) 0.007(0.240) 
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